The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde

Retina

Volumn 31, Issue 3, 2011, Pages 602-608

  Turk, Adem ^a   Nuhoglu, Irfan ^a   Mentese, Ahmet ^a   Karahan, Süleyman Caner ^a   Erdol, Hidayet ^a   Erem, Cihangir ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

albumins; diabetes mellitus; diabetic retinopathy; ischemia modified albumin; malondialdehyde; oxidative stress

Indexed keywords

ALBUMIN; GLUCOSE; HEMOGLOBIN A1C; ISCHEMIA MODIFIED ALBUMIN; MALONALDEHYDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; ISCHEMIA; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; ROC CURVE; SERUM ALBUMIN;

EID: 79952313042     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ed8cd1     Document Type: Article

References (39)

1. Lim MC, Lee SY, Cheng BC, et al. Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme. Ann Acad Med Singapore 2008;37:753-759.
2. Kempen JH, O'Colmain BJ, Leske MC, et al; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-563.
3. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci 2005;46:2328-2333.
4. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008;9:315-327.
5. Oshitari T, Roy S. Diabetes: a potential enhancer of retinal injury in rat retinas. Neurosci Lett 2005;390:25-30. (Pubitemid 41317784)
6. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
7. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-455. (Pubitemid 37536961)
8. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298:902-916. (Pubitemid 47311296)
9. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-135. (Pubitemid 36794505)
10. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871. (Pubitemid 18266031)
11. Gunduz A, Turedi S, Mentese A, et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008;26:874-878.
12. Gunduz A, Turkmen S, Turedi S, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 2009;16:539-543.
13. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - preliminary report. Dis Markers 2008;24:311-317.
14. Ukinc K, Eminagaoglu S, Ersoz HO, et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 2009;36:255-261.
15. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010;43:450-454.
16. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007;2007:43603.
17. El-Mesallamy H, Hamdy N, Suwailem S, Mostafa S. Oxidative stress and platelet activation: markers of myocardial infarction in type 2 diabetes mellitus. Angiology 2010;61:14-18.
18. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-1214. (Pubitemid 27297265)
19. Pan HZ, Zhang L, Guo MY, et al. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 2009. Epub ahead of print.
20. World Medical Association (WMA): Declaration of Helsinki. 1964. As amended by the WMA 52nd General assembly, Edinburgh, Scotland, October 2000.
21. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:823-833.
22. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-315.
23. Yagi K. Lipid peroxides and related radicals in clinical medicine. In: Armstrong D, ed. Free Radicals in Diagnostic Medicine. New York, NY: Plenum Press; 1994:1-15.
24. Armstrong D, Al-Awadi F. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic Biol Med 1991;11:433-436.
25. Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009;15:137.
26. Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V. Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008;49:260-266.
27. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006;108:410-411.
28. Gunduz A, Mentese A, Turedi S, et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia. Emerg Med J 2008;25:351-353. (Pubitemid 351833360)
29. Keating L, Benger JR, Beetham R, et al. The PRIMA study: presentation of ischemia-modified albumin in the emergency department. Emerg Med J 2006;23:764-768.
30. Turedi S, Gunduz A, Mentese A, et al. The value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007;25:770-773. (Pubitemid 47385040)
31. Mentese A, Mentese U, Turedi S, et al. Effect of deep vein thrombosis on ischaemia-modified albumin levels. Emerg Med J 2008;25:811-814.
32. Montagnana M, Lippi G, Volpe A, et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006;39:913-917. (Pubitemid 44363080)
33. Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007;23:216-220. (Pubitemid 46239165)
34. Peerapatdit T, Patchanans N, Likidlilid A, Poldee S, Sriratanasathavorn C. Plasma lipid peroxidation and antioxidant nutrients in type 2 diabetic patients. J Med Assoc Thai 2006;89:S147-S155. (Pubitemid 46193144)
35. Fenercioglu AK, Saler T, Genc E, Sabuncu H, Altuntas Y. The effects of polyphenol-containing antioxidants on oxidative stress and lipid peroxidation in type 2 diabetes mellitus without complications. J Endocrinol Invest 2010;33:118-124.
36. Gordon LA, Morrison EY, McGrowder DA, et al. Effect of exercise therapy on lipid profile and oxidative stress indicators in patients with type 2 diabetes. BMC Complement Altern Med 2008;8:21.
37. Turk HM, Sevinc A, Camci C, et al. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol 2002;39:117-122.
38. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008;86:683-687.
39. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 2006;20:1474-1475. (Pubitemid 44921215)